Soligenix Inc (OTC:SNGX)‘s stock had its “buy” rating reissued by investment analysts at Maxim Group in a research note issued to investors on Monday, StockTargetPrices.com reports. They presently have a $4.00 price objective on the stock.

Shares of Soligenix (OTC:SNGX) traded up 8.4406% during trading on Monday, reaching $2.1905. The company had a trading volume of 53,284 shares. The company’s market cap is $12.42 million. The firm has a 50 day moving average price of $2.49 and a 200 day moving average price of $2.60. Soligenix has a 12 month low of $2.09 and a 12 month high of $14.40.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/06/19/soligenix-inc-sngx-earns-buy-rating-from-maxim-group.html.

Soligenix Company Profile

Soligenix, Inc is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.

Stock Target Prices

Receive News & Ratings for Soligenix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix Inc and related companies with MarketBeat.com's FREE daily email newsletter.